Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

AstraZeneca

Moderna

Pfizer

Could these vaccine stocks be prime additions to your portfolio today?

Good Stocks To Buy Right Now? 4 Vaccine Stocks To Check Out

RADNOR, Pa., Dec. 23, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX).

NVAX CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces to Novavax, Inc. of Deadline in Securities Fraud Class Action Lawsuit

GAITHERSBURG, Md., Dec. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today announced the expansion of the companies' collaboration and license agreements for NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine.

Novavax and SK bioscience Expand Manufacturing Agreement

Pfizer, AstraZeneca, and Novavax will be important players in the next stages of the world's battle against the pandemic.

3 COVID Stocks to Fight Omicron

Despite NVAX stock being lower, Novavax announced promising data based on initial results of a study. Here's what you should know.

NVAX Stock: 5 Things to Know About Novavax's Omicron-Fighting News

Novavax's (NVAX) protein-based COVID vaccine shows a cross-reactivity response against the Omicron variant. It will also start clinical studies on an Omicron-specific vaccine in first-quarter 2022.

Novavax (NVAX) COVID-19 Booster Jab Effective Against Omicron

Novavax stock climbed early Thursday as the U.S. biotech said its Covid-19 vaccine produces an immune response to the Omicron variant, according to initial data.

Novavax Vaccine Produces Immune Response to Omicron.

Novavax Inc (NASDAQ: NVAX) said its two-dose COVID-19 vaccine effectively generates an immune response against the Omicron variant, according to early data. Though the company said neutralization against the Omicron variant was "4-fold lower" than it was against the original strain of the virus, suggesting that a booster shot or a new Omicron-specific vaccine would be beneficial.

Early Data Shows Novavax's COVID-19 Vaccine Triggers Immune Response To Omicron

Novavax said a third dose of its vaccine increased antibodies against omicron 73.5-fold from its initial two shots.

Novavax Covid Vaccine Provides Antibody Response Against Omicron, Data Suggests

Novavax Inc. shares were volatile in the extended session Wednesday after the biotech drug maker said initial data showed its COVID-19 vaccine booster showed immune responses against the omicron variant.

Novavax stock volatile following positive early COVID-19 vaccine data

- Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants - Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials, with a 9.3-fold IgG rise and a 19.9-fold ACE2 inhibition increase after booster dose - Immune responses in adolescents were 2- to 4-fold higher than adults against broad array of variants of interest and variants of concern - Development of Omicron-specific vaccine on track for initiation of GMP manufacturing in early January - Company to host investor conference call today from 4:30 - 5:00 pm ET GAITHERSBURG, Md., Dec. 22, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced initial data evaluating the immune response of its COVID-19 vaccine, NVX-CoV2373, against the Omicron variant as well as additional data from its ongoing Phase 2 boost study.

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies

New York, New York--(Newsfile Corp. - December 22, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than January 18, 2022 in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Novavax, Inc. ("Novavax") (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"). The...

NOVAVAX, INC. (NVAX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Novavax, Inc.

BioNTech SE

Ocugen, Inc.

Decreasing concerns about the omicron variant are leading to declining prices for these vaccine stocks.

Why BioNTech, Novavax, and Ocugen Stocks Are Slipping Today

Novavax (NVAX) initiates a phase III study to evaluate the booster dose of its COVID vaccine. WHO recommends administering the company's COVID vaccine booster to immunocompromised persons.

Novavax (NVAX) Commences COVID-19 Vaccine Booster Study

For Novavax, the vaccine approval is only the beginning. The company has a lot working in its favor and the sky is the limit for NVAX stock.

Novavax Has Finally Received The Much-Awaited Approval And The Stock Is Set To Soar

Boston, Massachusetts--(Newsfile Corp. - December 22, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ: NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email investors@tenlaw.com or call...

Thornton Law Firm Reminds Novavax, Inc. (NVAX) Investors of Securities Class Action Lawsuit

Novavax Inc's (NASDAQ: NVAX) first booster doses of NVX-CoV2373 have been administered in an extension of PREVENT-19 Phase 3 trial.  All PREVENT-19 trial participants are now eligible to receive a third booster dose of NVX-CoV2373.

Novavax Initiates Phase 3 COVID-19 Vaccine Booster Study

AbbVie

These three biotech stocks have performed amazingly well of late and are more than likely to perform even better next year. The post 3 of the Best Biotech Stocks for 2022 to Buy Now appeared first on InvestorPlace.

3 of the Best Biotech Stocks for 2022 to Buy Now

Abbott Labs

Cerner

Veracyte

Could these health care stocks be worth looking out for as the new year approaches?

Best Long Term Stocks To Buy? 4 Health Care Stocks For Your Watchlist

GAITHERSBURG, Md., Dec. 21, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the first booster doses of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant, have been administered in an extension of the company's PREVENT-19 pivotal Phase 3 clinical trial.

Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study

- WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends primary two-dose vaccination series of NVX-CoV2373 in persons aged 18 and older - SAGE recommends additional third dose of NVX-CoV2373 administered to immunocompromised persons - Recommendation follows grant of WHO Emergency Use Listing for Novavax' vaccine GAITHERSBURG, Md., Dec. 21, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) has published its interim recommendations for use of NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant.

World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine

NEW YORK, Dec. 21, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline. SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novavax, Inc. Investors With Losses to Secure Counsel Before Important January 11 Deadline in Securities Class Action - NVAX

Novavax (NVAX) secures approval for its COVID vaccine in the European Union. Following EU approval, WHO grants second emergency use listing to the company's COVID vaccine.

Novavax (NVAX) COVID Vaccine Gets EU Nod, 2nd Listing by WHO

On Monday, the European Commission announced that it has granted Novavax, Inc. ( NVAX , Financial) a Conditional Marketing Authorization (CMA) for the sale of its Covid-19 vaccine Nuvaxovid to the European Union (EU) countries. So far, Nuvaxovid is the fifth vaccine approved in the EU against the Covid-19 virus.

Novavax's Covid-19 Vaccine Is Finally Approved

2022 will be a watershed year for the company in more ways than one.

News for Novavax Stock (NVAX)